Should I Buy INMD? INMD 2026 Analysis

Should You Buy Inmode Ltd (INMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

15.080

1 Day change

1.75%

52 Week Range

19.780

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy (event-driven/speculative): At ~$15.11, INMD trades well below the $18/share non-binding proposal, creating near-term upside if the strategic review produces a deal or improved capital actions.
Catalyst window is immediate: Strategic alternatives process is active and earnings (QDec 2025) on 2026-02-10 pre-market can force a decisive move soon—fits an impatient, near-term setup.
Not a fundamentals-driven buy: Recent quarter showed sharp YoY declines; this is primarily a catalyst/price-action trade rather than a conviction growth entry.
Intellectia Proprietary Trading Signals: No strong proprietary “must-buy” trigger today (no AI Stock Picker or SwingMax entry), so the buy call relies on event catalyst + technical levels rather than a system signal.

Technical Analysis

Trend/MAs: Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader structure has improved versus longer-term trend.
Momentum: MACD histogram positive (0.127) but contracting, implying upside momentum exists but is weakening.
RSI: RSI(6) ~44.9 (neutral-to-soft), not oversold and not signaling a strong rebound on its own.
Key levels: Price (~15.11) is below Pivot 15.29 (slightly bearish near-term). Support: 14.23 (S1) then 13.57 (S2). Resistance: 16.35 (R1) then 17.01 (R2).
Pattern-based odds: Similar-pattern stats imply modest positive drift (~+1.22% next day, +3.9% next week), supportive but not decisive.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning vs flow: OI Put/Call 0.83 suggests slightly more call positioning (mildly constructive), but Volume Put/Call 1.36 shows near-term trading flow is put-skewed (short-term caution).
Activity: Today’s option volume is low in absolute terms (26 contracts) but shown as ~2.12x vs 30-day avg in the feed—suggesting a relative pickup.
Volatility: 30D IV ~53.75% vs HV ~52.2% (IV slightly above realized). IV percentile ~36 / IV rank ~18.9 indicates IV is not extremely elevated versus its own history—options aren’t pricing peak fear.

Technical Summary

Sell

Buy

Positive Catalysts

on 2026-02-10 (pre-market)** can quickly resolve sentiment and re-rate the stock if results/forward commentary stabilize.
can attract dip-buying on constructive news.

Neutral/Negative Catalysts

- Deal uncertainty: Proposal is non-binding and for 51%; strategic review may end without an attractive transaction, which could remove the takeover premium.
- Fundamental deterioration: Recent YoY declines in revenue, EPS, and net income weaken the “core” thesis if catalysts fade.
- Short-term tape weakness: Stock fell -5.53% in the regular session and is below the pivot (15.29).
- Options flow caution: Put-heavy volume (put/call 1.36) signals near-term hedging/speculation to the downside.
- No influential buying signal: No insider trend and no recent Congress trading data to confirm accumulation from notable cohorts.

Financial Performance

Latest reported quarter: 2025/Q3
Revenue: 93.17M, -28.46% YoY (meaningful contraction).
Net Income: 21.86M, -57.12% YoY (profitability compressed sharply).
EPS: 0.34, -47.69% YoY.
Gross Margin: 77.61%, -4.81% YoY (still high margin profile, but trending down).
Read-through: Financial trend is negative YoY; any sustained upside likely needs stabilization in growth or a corporate action (deal/buybacks/strategic outcome).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent stance: Street tone is Neutral/Hold.
Canaccord (2025-12-17): Price target cut to $15 from $16, rating Hold.
UBS (2025-11-06): Price target $16 (from $16.25), rating Neutral.
Pros (Wall St. view): Depressed smid-cap med-tech valuations + sector M&A backdrop can support interest; modest targets ($15–$16) suggest limited fundamental upside without catalysts.
Cons (Wall St. view): Repeated target trims imply reduced confidence in near-term operating performance; current price already near the low-end of targets, so upside is more catalyst-dependent than analyst-driven.

5 Analyst Rating

Wall Street analysts forecast INMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMD is 17.33 USD with a low forecast of 15 USD and a high forecast of 21 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

4 Hold

0 Sell

Hold

Current: 14.820

Low

Averages

17.33

High

Current: 14.820

Low

Averages

17.33

High

Canaccord

Hold

downgrade

$16 -> $15

AI Analysis

2025-12-17

Reason

Canaccord

Price Target

$16 -> $15

AI Analysis

2025-12-17

downgrade

Hold

Reason

Canaccord lowered the firm's price target on InMode to $15 from $16 and keeps a Hold rating on the shares. The firm said they are bullish on the Med-Tech sector heading into 2026 as they expect investor interest given smid-cap valuations continue to remain depressed, while M&A has picked up and the IPO market has opened in some respects. They also highlight how AI is changing our space, enabling improved patient outcomes, increased procedure volumes, more efficiency at the corporate level, and improved surgical accuracy/reproducibility, which they believe could drive some of the greatest changes in healthcare at a time when the system is capacity constrained and in desperate need of solutions.

UBS

Neutral

downgrade

$16

2025-11-06

Reason

UBS

Price Target

$16

2025-11-06

downgrade

Neutral

Reason

UBS lowered the firm's price target on InMode to $16 from $16.25 and keeps a Neutral rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INMD

Unlock Now

INMD Should I Buy

INMD Should I Buy

Should You Buy Inmode Ltd (INMD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch